MedTrace Logo

Open-label Follow-up Trial of Fixed Dose Combination of Telmisartan + Hydrochlorothiazide in Hypertensive Patients

NCT00267943 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 639

Last updated 2013-11-13

No results posted yet for this study

Summary

The primary objective is to assess the efficacy and safety of the fixed dose combination of telmisartan 80 mg + hydrochlorothiazide 25 mg (T80/H25) alone or in addition to other antihypertensive therapies during open-label, long-term treatment.

Conditions

Interventions

DRUG

telmisartan 80 mg + hydrochlorothiazide 25 mg

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim Study Coordinator · BIL UK / Ireland

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2007-01-31
Completion
2007-01-31

Countries

  • Denmark
  • Finland
  • France
  • Germany
  • Hong Kong
  • Ireland
  • Italy
  • Malaysia
  • Netherlands
  • Norway
  • South Africa
  • South Korea
  • Spain
  • Sweden
  • Switzerland
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00267943 on ClinicalTrials.gov